Plafibride: clinical trial of a new platelet antiaggregating agent.
A clinical study with a new anti-aggregant preparation; N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104), is shown in this paper. A double blind study, was carried out comparing its effects with those of a well known antiaggregant agent, dipyridamole. No clinical nor analytical side effects of importance were observed.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013997:Time Factors
D002995:Clofibric Acid; C016894:plafibride; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D002994:Clofibrate